Type 2 Diabetes

The American College of Physicians released new recommendations for the management of type 2 diabetes with inadequate glycemic control using metformin or other first-line therapies.

During this Q&A interview, Crandall discussed the takeaways from her portion of an ACP conference presentation on current clinical guidelines in type 2 diabetes.

Meta-analysis of 11 phase 3 trials shows SGLT2 inhibitors reduce cardiovascular event risk by 9% across diverse patient populations.

The proposed insulin glargine biosimilar (Basalin) showed comparable immunogenicity, efficacy, and safety to the originator (Lantus) in a phase 3 equivalence trial.

Prices of nearly all insulins, SGLT2 inhibitors, and GLP1As could be reduced if robust generic or biosimilar manufacture were enabled.

In this endocrinology month in review for March 2024, we recap the most popular FDA news and pipeline updates as well as recognizing the 2-year anniversary of Diabetes Dialogue.

On March 08, 2024, the FDA approved semaglutide 2.4 mg (Wegovy) to reduce cardiovascular risk in adults with obesity or overweight and heart disease based on the SELECT trial.

On March 07, 2024, Novo Nordisk provided updates on semaglutide 2.4 mg as well as the development programs cagrisema, monlunabant, and amycretin.

In our endocrinology month in review for February 2024, we are spotlighting trending studies and new data in endocrinology, the latest news surrounding tirzepatide, and a recap of the 4 episodes of our flagship endocrinology podcast launched during the last month.

Seropositivity was associated with greater albuminuria but not peripheral artery disease in a cohort of patients ≥ 50 years of age with type 2 diabetes mellitus.

Initiation of SGLT2 inhibitors reduced the risk of composite anemia outcomes, compared with GLP-1 RA, among patients with type 2 diabetes and CKD.

The FDA has greenlit Dexcom's Stelo Glucose Biosensor System, marking a historic first as the first continuous glucose monitors to be available over-the-counter.

Results of a new analysis underscore the significance of sleep health in mitigating type 2 diabetes risk, revealing that even an optimal diet may not fully offset the negative impact of inadequate sleep.

Novo Nordisk announced topline data from the FLOW trial indicate semaglutide 1.0 mg (Ozempic) was associated with a 24% reduction in risk of kidney disease-related events among individuals with type 2 diabetes and CKD compared to placebo therapy.

A secondary analysis of cross-sectional data found that serum albumin levels negatively correlated with the prevalence of diabetic retinopathy.

The analysis of several oral antidiabetic drugs revealed patients taking SGLT2 inhibitors had more NAFLD regression and fewer adverse liver-related outcomes.

A new analysis cites relatively high hemoglobin levels as a protective factor for bone quality in patients with type 2 diabetes.

A new study found balance and falling were linked to an increased risk of all-cause mortality, as well as cause-specific mortality from cardiovascular disease and diabetes.

A new proof-of-concept observation study reports the dual GLP-1/GIP agonist's positive efficacy and safety for adults with T1D.

Testosterone replacement therapy did not differ significantly from placebo in preventing diabetes progression in a substudy of the TRAVERSE randomized trial.

Tirzepatide, a dual GLP-1/GIP agonist approved for diabetes and obesity, was associated with significant blood pressure reductions in an analysis of the SURMOUNT-1 trial.

This endocrinology month in review spotlights FDA news, a pair of studies examining cardiovascular and renal risk reduction in type 2 diabetes, results from a subtrial examining testosterone’s effect on fracture risk, and 4 new episodes of diabetes dialgoue

Compared to glucagon-like peptide 1 receptor agonists and dipeptidyl peptidase 4 inhibitors, Use of sodium-glucose cotransporter 2 inhibitors was linked to a decreased risk of nephrolithiasis in patients with type 2 diabetes.

A systematic review of over 400 studies in type 2 diabetes reveals 13 biomarkers, including NT-proBNP and troponin-t, with potential to significantly enhance cardiovascular disease risk prediction.

Evidence from the Look AHEAD study suggests achieving remission in type 2 diabetes is associated with risk reductions in chronic kidney disease and cardiovascular disease.

Improvements in insulin resistance were reported in patients with RA and type 2 diabetes treated with tofacitinib.

In this episode, hosts discuss recent news and updates in diabetes technology from Abbott, Dexcom, and Medtronic in the first half of January 2024.

In this episode, hosts sit down with Ralph DeFronzo, MD, for a discussion on how advances in management have transformed the diagnosis and management of hypercortisolism among people with type 2 diabetes.

A study of more than 140 adults with diabetes is providing additional insight into the prevalence of anemia among these patients as well as its association with changes in glycemic control.

Applied Therapeutics announced topline results from ARISE-HF on January 04, 2023 and plans to present full results at an upcoming medical conference.